Lou Gehrig’s disease is an aggressive neurodegenerative disorder that is characterized by the degeneration of motor neurons. This degeneration steadily progresses, negatively affecting the afflicted individual’s neural functions. This ultimately leads to paralysis and death from respiratory failure. For both the afflicted individual and their family, Lou Gehrig’s disease places both physical and emotional burdens on them, highlighting the need for new therapies. Current medical treatments are limited to the management of the symptoms and do not provide any assistance in the disease slowly progressing. This study, therefore, proposes the regeneration of UC-MSCs from within a specialized Stem Cell Clinic. The major paradigm shift that can be achieved by the cellular therapy that is of the potential to reverse the cellular dysfunction and pathology.
Lou Gehrig’s disease Pathology
In order to develop a treatment approach, first, the pathophysiology of Lou Gehrig’s disease must be understood. The progression of Lou Gehrig’s disease results in glutamate excitotoxicity, mitochondrial damage and severe inflammation of the nervous system. The neurons that control the motor functions undergo cell death after being subjected to abnormally high levels of calcium because of the poor removal of glutamate. Moreover, the resident immune cells of the central nervous system are also affected. Microglia and astrocytes move from a supportive and protective role to a toxic and inflammatory role. These cells damage the nervous system due to the release of reactive oxygen species and cytokines. The subsequent inflammatory state of the microenvironment leads to motor neuron cell death. A certain medical facility aims to interrupt a specific neuroinflammatory cycle. Through unique cell therapies, clinicians attempt to reshape the aggressiveness of the surrounding neural tissue and stop negative glial reactions while allowing the remaining motor pathways to purposely die.
Figure 1: The pathophysiology and Treatment target of Lou Gehrig’s disease
Traditional Medical of Lou Gehrig’s disease Approaches
In the past, the management of Lou Gehrig’s disease relied on neuroprotective agents such as riluzole and edaravone. Riluzole is thought to act by inhibiting glutamate release and thus may help reduce synaptic excitotoxicity. On the other hand, edaravone is a free radical scavenger aimed at decreasing oxidative stress in the central nervous system. Although the aforementioned agents may marginally prolong survival by only several months, there is no regeneration of motor neurons and no meaningful improvement of function. The most considerable constraint of such therapies is the inability to manage the plurality of the disease. Instead, they individually manage downstream effects of the disease, while the progressive neurodegenerative process continues to overwhelm. The adverse effects of such medications on the liver and gastrointestinal system further complicate their long-term use. These aspects explain the rationale for the development of alternative biological approaches at a regenerative medical facility.
Principles of Cellular Regeneration
With respect to regenerative approaches, UC-MSCs may be have considerable potential for a number of reasons. In comparison to most synthetic pharmaceuticals, UC-MSCs have a greater potential to achieve a range of effects primarily as result of their robust paracrine signaling. Upon introduction to a patient, UC-MSCs secrete a range of biologically active agents. Notably, several neurotrophic factors such as brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are included in the range. These neurotrophic factors have been shown to promote the survival of motor neurons and enhance the regeneration of motor neurons. In addition, UC-MSCs can also break down the toxic neuroinflammation of Lou Gehrig’s disease. These help alter the microglia from the harmful M1 to the neuroprotective M2, therefore reducing the secretion of the neuroinflammatory cytokines and reversing inflammation. The therapies can be custom-designed to assist the dying neurons, thus reducing the target neural deprivation during the care-taking at the specialized stem cells clinics.
Figure 2: Comparative Approaches of traditional and cellular regeneration in Lou Gehrig’s disease
Dispersed Economic Engineering
There is rapid movement to integrate regenerative technologies in the engineering of Lou Gehrig’s disease in Southeast Asia. Thailand is emerging as one of the key frontiers for these advanced therapies. This is due to the world-class medical facilities, state-of-the-art biomedical research, as well as the progressive but restrictive legislations concerning cellular therapies. In this context, a prominent Stem Cell Clinic in Thailand is able to deliver therapies utilizing UC-MSCs at a considerably cheaper rate than is possible in Western countries. Additionally, Thai Research Centers have existing relationships with international leaders in the cryopreservation and delivery of stem cells. This geographic placement allows patients to remain in an environment that is supportive of the care, and combines advanced medical expertise along with gentle therapeutic care.
Final Thoughts
The challenges presented by Lou Gehrig’s disease are multisystemic and require the ability to think outside the box for integrating the complex biotechnologies. The ability to aid patient recovery from the relentless damage of neuroinflammation is an urgent need. The paradigm-shifting strategy can be exemplified by the deployment of UC-MSCs. These cells target the root of the disease by utilizing their potent secretome and immunomodulatory capacity. As the field continues to advance, the treatment of patients at a specialized Stem Cell Clinic, especially in the cutting-edge medical centers in Thailand, is likely to be an integral part of the future of neurology. In the end, the progress of cellular therapy continues to provide hope for the modification of this destructive neurodegenerative disorder.